Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma.

IF 4 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Digestive and Liver Disease Pub Date : 2025-01-01 Epub Date: 2024-06-08 DOI:10.1016/j.dld.2024.05.027

Chang-Sheng Xia, Marcin Krawczyk, Chun Di, Łukasz Krupa, Beata Kruk, Piotr Krawczyk, Piotr Milkiewicz, Huizhang Bao, Xiao He, Damin Liu, Chunhong Fan, Abdullah Nasser, Steffi Lopens, Frank Ulrich Weiss, Fabian Frost, Peter Schierack, Dirk Roggenbuck, Yudong Liu

{"title":"Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma.","authors":"Chang-Sheng Xia, Marcin Krawczyk, Chun Di, Łukasz Krupa, Beata Kruk, Piotr Krawczyk, Piotr Milkiewicz, Huizhang Bao, Xiao He, Damin Liu, Chunhong Fan, Abdullah Nasser, Steffi Lopens, Frank Ulrich Weiss, Fabian Frost, Peter Schierack, Dirk Roggenbuck, Yudong Liu","doi":"10.1016/j.dld.2024.05.027","DOIUrl":null,"url":null,"abstract":"Background: Anti-glycoprotein 2 (anti-GP2) IgA and antineutrophil-cytoplasmic antibodies to proteinase 3 (PR3-ANCA) have been reported as predictive markers of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC), but their prevalence in CCA patients without PSC remains unclear.Methods: This study involved Asian discovery (n = 118) and European validation (n = 38) cohorts of CCA patients without PSC, alongside 49 Asian and 82 European pancreatic ductal adenocarcinoma (PDAC) patients, 21 with benign pancreatic neoplasms (BPN) and 45 with hepatocellular carcinoma (HCC), and 157 healthy controls (HC) from Asia and Europe. We analyzed the prevalence of PR3-ANCA, IgA and IgG against GP21 and GP24, and the CA19-9 levels.Results: Anti-GP21 IgA was the most prevalent in both CCA cohorts (discovery: 55.1 %; validation: 42.1 %) and significantly higher than in other groups except PDAC (all p < 0.05). It demonstrated the best diagnostic performance in distinguishing CCA from disease controls and HC, outperforming tumor markers. No significant correlation was found between anti-GP21 IgA levels and CA19-9 levels.Conclusion: Our findings show that anti-GP21 IgA revealing the loss of mucosal tolerance is a potential novel diagnostic biomarker for CCA.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":"14-22"},"PeriodicalIF":4.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.dld.2024.05.027","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Anti-glycoprotein 2 (anti-GP2) IgA and antineutrophil-cytoplasmic antibodies to proteinase 3 (PR3-ANCA) have been reported as predictive markers of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC), but their prevalence in CCA patients without PSC remains unclear.

Methods: This study involved Asian discovery (n = 118) and European validation (n = 38) cohorts of CCA patients without PSC, alongside 49 Asian and 82 European pancreatic ductal adenocarcinoma (PDAC) patients, 21 with benign pancreatic neoplasms (BPN) and 45 with hepatocellular carcinoma (HCC), and 157 healthy controls (HC) from Asia and Europe. We analyzed the prevalence of PR3-ANCA, IgA and IgG against GP2₁ and GP2₄, and the CA19-9 levels.

Results: Anti-GP2₁ IgA was the most prevalent in both CCA cohorts (discovery: 55.1 %; validation: 42.1 %) and significantly higher than in other groups except PDAC (all p < 0.05). It demonstrated the best diagnostic performance in distinguishing CCA from disease controls and HC, outperforming tumor markers. No significant correlation was found between anti-GP2₁ IgA levels and CA19-9 levels.

Conclusion: Our findings show that anti-GP2₁ IgA revealing the loss of mucosal tolerance is a potential novel diagnostic biomarker for CCA.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

失去粘膜对糖蛋白 2 同工酶 1 的耐受性是胆管癌潜在的新型诊断生物标志物。

背景：抗糖蛋白2（anti-GP2）IgA和抗中性粒细胞-细胞质蛋白酶3抗体（PR3-ANCA）已被报道为原发性硬化性胆管炎（PSC）患者胆管癌（CCA）的预测标志物，但它们在无PSC的CCA患者中的流行率仍不清楚：本研究涉及亚洲发现（118 人）和欧洲验证（38 人）队列中无 PSC 的 CCA 患者、49 名亚洲和 82 名欧洲胰腺导管腺癌（PDAC）患者、21 名良性胰腺肿瘤（BPN）患者和 45 名肝细胞癌（HCC）患者，以及来自亚洲和欧洲的 157 名健康对照（HC）。我们分析了 PR3-ANCA、抗 GP21 和 GP24 的 IgA 和 IgG 以及 CA19-9 水平的患病率：结果：抗 GP21 IgA 在两组 CCA 中的发病率最高（发现率：55.1%；验证率：42.1%），明显高于除 PDAC 以外的其他组别（均 p < 0.05）。在将 CCA 与疾病对照组和 HC 区分开来方面，它的诊断性能最佳，优于肿瘤标记物。抗 GP21 IgA 水平与 CA19-9 水平之间未发现明显相关性：我们的研究结果表明，揭示粘膜耐受性丧失的抗 GP21 IgA 是一种潜在的新型 CCA 诊断生物标记物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Digestive and Liver Disease 医学-胃肠肝病学

CiteScore

6.10

自引率

2.20%

发文量

632

审稿时长

19 days

期刊介绍： Digestive and Liver Disease is an international journal of Gastroenterology and Hepatology. It is the official journal of Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Pancreas (AISP); Italian Association for Digestive Endoscopy (SIED); Italian Association for Hospital Gastroenterologists and Digestive Endoscopists (AIGO); Italian Society of Gastroenterology (SIGE); Italian Society of Pediatric Gastroenterology and Hepatology (SIGENP) and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease publishes papers on basic and clinical research in the field of gastroenterology and hepatology. Contributions consist of: Original Papers Correspondence to the Editor Editorials, Reviews and Special Articles Progress Reports Image of the Month Congress Proceedings Symposia and Mini-symposia.